Skip to content

A Clinical Trial of Shengmai Zhenwu Granules for the Treatment of Chronic Heart Failure with Preserved Ejection Fraction

A Clinical Trial of Shengmai Zhenwu Granules for the Treatment of Chronic Heart Failure with Preserved Ejection Fraction

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025002163
Enrollment
Unknown
Registered
2025-11-08
Start date
2024-03-05
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Heart Failure with Preserved Ejection Fraction

Interventions

Sponsors

Shanghai Municipal Hospital of Traditional Chinese Medicine Affiliated to Shanghai University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) Aged 18-70 years, regardless of gender; (2) Manifesting typical clinical presentations and meeting the diagnostic criteria for heart failure with preserved ejection fraction (HFpEF) (left ventricular ejection fraction (LVEF) = 50%); (3) Patients classified as New York Heart Association (NYHA) functional class I-III; (4) In good mental state and capable of verbal and written communication; (5) Patients who have provided informed consent to voluntarily participate in the trial, demonstrate strong compliance, and are able to cooperate with the investigation.

Exclusion criteria

Exclusion criteria: (1) Complicated with other cardiac disorders, or severe cardiopulmonary insufficiency, or severe cardiac arrhythmia; (2) Complicated with severe primary diseases of the liver, kidney, hematopoietic system, etc.; (3) Suspected or confirmed history of alcohol or drug abuse, or other conditions which, in the judgment of the investigator, may reduce the likelihood of enrollment or complicate enrollment, such as frequent changes in work environment that may easily lead to loss to follow-up; (4) Individuals with allergic constitution; (5) Individuals with severe inflammatory diseases; (6) Patients with psychiatric disorders; (7) Pregnant or lactating women; (8) Those currently participating in other clinical trials.

Design outcomes

Primary

MeasureTime frame
N-terminal pro-B-type Natriuretic Peptide (NT-proBNP);

Secondary

MeasureTime frame
NYHA Functional Classification;Six-minute Walk Distance (6MWD);TCM Syndrome Score;

Countries

China

Contacts

Public ContactSanqiu Zhao

Shanghai Municipal Hospital of Traditional Chinese Medicine Affiliated to Shanghai University of Traditional Chinese Medicine

1850289284@qq.com+86 15026127062

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026